NPO Microgen company vision

Creation of a multi-profile association with production facilities, financial resources and highly-qualified personnel which will achieve the main goal of FGUP NPO Microgen, which is ensuring sanitary and epidemiologic welfare in the Russian Federation. The new unified company vision includes such priority areas of business as investments in modernization of production facilities and scientific research and development projects.

In collaboration with leading Russian scientists FGUP NPO Microgen is striving to develop and manufacture new high-quality medical preparations and state-of-the-art pharmaceutical forms (nasal sprays, emulsions, etc.). At present more than 15 novel preparations are being launched, among them new influenza, smallpox and tick-borne encephalitis vaccines, combined vaccines, a diphtheria-tetanus-pertussis vaccine and a Haemophilus influenzae vaccine; measles, mumps and rubella vaccines, a swine influenza vaccine, and an acellular pertussis vaccine, together with a Staphylococcus-Proteus-Pseudomonas vaccine and other products.

Company strategy

A strategic aim of FGUP NPO Microgen is to become a leader among global pharmaceutical companies by developing new markets, diversification of the medicinal products it produces and by ensuring stable supplies.

A peculiarity of FGUP NPO Microgen and one of its strong points is its functioning as both the manufacturer and supplier of medical immunobiological preparations. This is an enterprise with a powerful resource base and branched sales infrastructure.